Drug
Istradefylline 40 mg
Istradefylline 40 mg is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_3
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
terminated133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
terminated
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
NCT05182151
completedphase_3
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
NCT01968031
completedphase_1
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
NCT02174250
Clinical Trials (3)
Showing 3 of 3 trials
NCT05182151
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
NCT01968031Phase 3
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
NCT02174250Phase 1
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3